High Intensity Contact Ultrasound Interstitial Medical Device

A new vision of surgery

“Surgery is undergoing rapid changes. Vascular diseases are now treated using endovascular techniques and extravascular pathologies are now treated using endoscopic and robotic techniques. This represents a significant change for the surgeon, who has the desire to minimize the aggressiveness of his actions. However, in the near future, these endoscopic and robotic techniques should give way to pure percutaneous techniques. Soon surgery will no longer be “open, sleep, pain and hospitalization,” but rather “diagnose, phenotype, coagulate, resect” and this will be done safely because all procedures will be performed under continuous image monitoring. This is the surgery of tomorrow. This change may seem impossible. Yet it is possible.” Pr Carpentier

This is the goal of the research performed by CarThera: develop a totally new medical technology that can be performed in a single outpatient procedure, under local anesthesia and using real-time MRI monitoring.

Between 2006 and 2009, Pr. Alexandre Carpentier, in collaboration with an American team, performed two clinical trials using a probe that emits laser energy to destroy brain tumors under real-time MRI control (A. Carpentier et al., Journal of Neurosurgery 2008; A. Carpentier et al., Lasers in Surgery and Medicine, 2011; A. Carpentier et al., Lasers in Surgery and Medicine, 2012). 

le monde couverture paint2

This first human trial allowed CarThera® to highlight the benefits of the use of MRI as an interventional tool and significantly increased patient survival (+12.8 months). But, several limitations were also noted: it was difficult to use the laser probe for treating complex tumor shapes; histological diagnosis during the procedure was not possible; and, it was not possible to extract necrotic tissue after the procedure, which created an undesirable mass effect after treatments.






The SonoProbe

At CarThera, we wanted to solve those three issues by developing a new probe that contains two major innovations:

(i) changing the energy source for inducing heating of tissue from a laser to ultrasound to allow for a better adaptation of the thermal treatment to the tumor shape without having to move the probe.

(ii) adding a central canal to the device to allow the surgeon to perform biopsies at the beginning of the treatment and to perform tissue removal at the end of the treatment to decrease the mass effect.

This is how the SonoProbe program was born.


  • unnamed-2

  • News CarThera

    December 2020: CarThera starts phase I/II trial in collaboration with Northwestern University

    CarThera announces the launch of a new phase I/II clinical trial (NCT04528680) in collaboration with Northwestern University in Chicago. The trial will recruit up to 39 patients with recurrent glioblastoma (GBM) to test the SonoCloud-9 device in combination with Abraxane® – an albumin-bound formulation of paclitaxel. The first patient in this trial has been treated and further patient recruitment is now on-going. The goal of the trial is to determine the safe dose of Abraxane to be used in combination with the SonoCloud-9 device in recurrent GBM patients (Phase I); then expand with the established safe dose in order to evaluate preliminary efficacy (Phase II).

    September 2020: CarThera to receive €2M grant and €10.5M equity from the European Innovation Council

    CarThera announces that it has been selected by the EIC Accelerator Pilot to receive a €2 million ($2.3M) grant and €10.5M ($12M) in equity for the development of its DOMEUS project for the treatment of glioblastoma (GBM) patients. The company will also receive business coaching and mentoring to accompany its growth. With the DOMEUS project, CarThera will be able to scale-up its processes and organizational structure to bring its technology to an increasing number of patients around the world.

    June 2020: CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

    CarThera announces that the first patient has been enrolled and treated in a clinical trial evaluating the safety of using its SonoCloud® technology in combination with checkpoint inhibitors for the treatment of brain metastases from melanoma (NCT04021420). In this trial, anti-PD1 alone or in combination with anti-CTLA4 are administered in patients before SonoCloud-mediated Blood Brain Barrier opening (BBB). BBB opening can help boost the brain’s immunity and increase brain penetration of newly approved systemically delivered immunotherapies, such as checkpoint inhibitors. This could translate into controlling brain disease with the same magnitude as peripheral diseases, improving clinical outcomes for many patients worldwide.